Image 3_Sediment exposure decreases diversity in the surface mucus layer microbiome of Porites lobata at Honoliʻi, Hawaiʻi.jpeg by Joseph W. P. Nakoa (21796214)

Image 1_Sediment exposure decreases diversity in the surface mucus layer microbiome of Porites lobata at Honoliʻi, Hawaiʻi.jpeg by Joseph W. P. Nakoa (21796214)

Table 1_Sediment exposure decreases diversity in the surface mucus layer microbiome of Porites lobata at Honoliʻi, Hawaiʻi.xlsx by Joseph W. P. Nakoa (21796214)

Image 12_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

Table 1_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.docx by Yaping Chu (789771)

Image 14_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

Image 1_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

Image 11_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

Image 16_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

Image 13_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

Image 3_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

Image 15_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

Image 2_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

Image 10_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

Table_2_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.xlsx by Kristin R. Anderson (5478734)

Image_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.jpg by Kristin R. Anderson (5478734)

Table_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.pdf by Kristin R. Anderson (5478734)

Significantly decreased necrosis observed on wheat leaves inoculated with <i>ΔZtknr4</i>. by Erika Kroll (20537020)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”